Skip to main content
. 2008 Apr 16;2008(2):CD005589. doi: 10.1002/14651858.CD005589.pub2

Comparison 1. Carboplatin/paclitaxel/topotecan versus Carboplatin/paclitaxel.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1.1 Overall survival (Bookman 2009) 1   Other data No numeric data
1.2 Overall survival (Placido 2004) 1   Other data No numeric data
1.3 Pool analysis of OS HR 2   Hazard Ratio (IV, Fixed, 95% CI) 1.02 [0.99, 1.06]
1.4 Time to progression (Placido 2004) 1   Other data No numeric data
1.4.1 Median time to progression(by month) 1   Other data No numeric data
1.5 PFS (Bookman 2009) 1   Other data No numeric data
1.6 PFS (Placido 2004)) 1   Other data No numeric data
1.7 Pool analysis of PFS HR 2   Hazard Ratio (IV, Fixed, 95% CI) 1.03 [1.03, 1.03]
1.8 toxicity (Placido 2004) 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
1.8.1 leukopenia‐overall 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 189.62 [11.89, 3022.93]
1.8.2 leukopenia‐grade 3/4 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 80.41 [4.99, 1294.66]
1.8.3 neutropenia‐overall 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 179.69 [11.27, 2865.82]
1.8.4 neutropenia‐grade 3/4 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 130.05 [8.13, 2080.23]
1.8.5 thrombocytopenia‐overall 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 134.02 [8.38, 2143.07]
1.8.6 thrombocytopenia‐grade 3/4 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 52.62 [3.24, 854.79]
1.8.7 anemia‐overall 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 157.85 [9.89, 2520.16]
1.8.8 anemia‐grade 3/4 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 20.85 [1.23, 352.28]
1.8.9 fever 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 12.91 [0.73, 226.87]
1.8.10 nausea/vomitting 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 110.20 [6.88, 1766.00]
1.8.11 diarrhea 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 22.83 [1.36, 383.66]
1.8.12 mucositis 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 20.85 [1.23, 352.28]
1.8.13 cutaneous 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 2.98 [0.12, 72.47]
1.8.14 liver 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 20.85 [1.23, 352.28]
1.8.15 cystitis 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 6.95 [0.36, 133.27]
1.8.16 peripheral neurophathy 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 40.70 [2.49, 666.29]
1.8.17 hypersensitivity 1 273 Risk Ratio (M‐H, Fixed, 95% CI) 4.96 [0.24, 102.44]